Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neoplasms, Glandular and Epithelial

Conditions

Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough, Poliomyelitis

Trial Timeline

May 1, 2006 → May 1, 2007

NCT ID

NCT00337428

About Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant)

Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF) + Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF) + Comparator: REPEVAX™ (Concomitant) + Comparator: REPEVAX™ (Non-Concomitant) is a phase 3 stage product being developed by Merck for Neoplasms, Glandular and Epithelial. The current trial status is completed. This product is registered under clinical trial identifier NCT00337428. Target conditions include Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms, Glandular and Epithelial were approved

Approved (20) Terminated (2) Active (0)

✅LenvatinibEisaiApproved

✅Eribulin mesylateEisaiApproved

✅Eribulin MesylateEisaiApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved

✅Chlorhydrate de RopivacaineAstraZenecaApproved

✅Sitagliptin + placeboMerckApproved

✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00337428	Phase 3	Completed	May 1, 2006	May 1, 2007	Neoplasms, Glandular and Epithelial

Competing Products

20 competing products in Neoplasms, Glandular and Epithelial

See all competitors

Product	Company	Stage	Hype Score
ADC-1013	Alligator Bioscience AB	Phase 1	19
AB0024	Gilead Sciences	Phase 1	29
TTI-237	Pfizer	Phase 1	21
852A	Pfizer	Phase 1	29
Pemetrexed	Eli Lilly	Phase 2	35
IMC-3C5	Eli Lilly	Phase 1	29
LY3295668	Eli Lilly	Phase 1/2	32
Galunisertib + Gemcitabine + Placebo	Eli Lilly	Phase 1/2	32
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	44
LY2784544	Eli Lilly	Phase 1	29
enzastaurin	Eli Lilly	Phase 2	35
Abemaciclib + Darolutamide + LHRH agonist/antagonist	Eli Lilly	Phase 1	29
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
120 mg LY2784544	Eli Lilly	Phase 2	39
LY4337713	Eli Lilly	Phase 1	36
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg	Vincerx Pharma	Phase 1	19
VIP236 (Q3W) + VIP236 (Q2W)	Vincerx Pharma	Phase 1	19